Nature Communications (Feb 2020)
A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity
- Louisa Nelson,
- Anthony Tighe,
- Anya Golder,
- Samantha Littler,
- Bjorn Bakker,
- Daniela Moralli,
- Syed Murtuza Baker,
- Ian J. Donaldson,
- Diana C. J. Spierings,
- René Wardenaar,
- Bethanie Neale,
- George J. Burghel,
- Brett Winter-Roach,
- Richard Edmondson,
- Andrew R. Clamp,
- Gordon C. Jayson,
- Sudha Desai,
- Catherine M. Green,
- Andy Hayes,
- Floris Foijer,
- Robert D. Morgan,
- Stephen S. Taylor
Affiliations
- Louisa Nelson
- Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Cancer Research Centre
- Anthony Tighe
- Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Cancer Research Centre
- Anya Golder
- Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Cancer Research Centre
- Samantha Littler
- Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Cancer Research Centre
- Bjorn Bakker
- European Research Institute for the Biology of Ageing (ERIBA), University of Groningen, University Medical Center Groningen
- Daniela Moralli
- Wellcome Centre Human Genetics, University of Oxford, Roosevelt Drive
- Syed Murtuza Baker
- Genomic Technologies Core Facility, Faculty of Biology, Medicine and Health, University of Manchester
- Ian J. Donaldson
- Genomic Technologies Core Facility, Faculty of Biology, Medicine and Health, University of Manchester
- Diana C. J. Spierings
- European Research Institute for the Biology of Ageing (ERIBA), University of Groningen, University Medical Center Groningen
- René Wardenaar
- European Research Institute for the Biology of Ageing (ERIBA), University of Groningen, University Medical Center Groningen
- Bethanie Neale
- NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre
- George J. Burghel
- Genomic Diagnostic Laboratory, St Mary’s Hospital, Central Manchester NHS Foundation Trust
- Brett Winter-Roach
- Department of Gynaecological Surgery, The Christie NHS Foundation Trust
- Richard Edmondson
- Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Cancer Research Centre
- Andrew R. Clamp
- Department of Medical Oncology, The Christie NHS Foundation Trust
- Gordon C. Jayson
- Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Cancer Research Centre
- Sudha Desai
- Department of Histopathology, The Christie NHS Foundation Trust
- Catherine M. Green
- Wellcome Centre Human Genetics, University of Oxford, Roosevelt Drive
- Andy Hayes
- Genomic Technologies Core Facility, Faculty of Biology, Medicine and Health, University of Manchester
- Floris Foijer
- European Research Institute for the Biology of Ageing (ERIBA), University of Groningen, University Medical Center Groningen
- Robert D. Morgan
- Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Cancer Research Centre
- Stephen S. Taylor
- Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Cancer Research Centre
- DOI
- https://doi.org/10.1038/s41467-020-14551-2
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 18
Abstract
High-grade serous ovarian carcinoma is often associated with TP53 mutation and chromosomal instability (CIN). Here, the authors generate ex vivo cultures from biopsies and ascites of patients and perform characterization to evaluate CIN mechanisms and compare drug sensitivity with patient responses.
